We attempted investigation of combined Smo and STAT3 inhibitor treatment in vivo; however, due to the potency of Smo inhibitors alone in our murine model, resulting in tumor eradication for many months, the model is not adequate for investigating synergy or Smo inhibitor resistance in vivo. The gene discussed is STAT3; the disease is neoplasm.